Media stories about Ritter Pharmaceuticals (NASDAQ:RTTR) have been trending somewhat positive this week, Accern Sentiment reports. The research group identifies negative and positive news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Ritter Pharmaceuticals earned a coverage optimism score of 0.01 on Accern’s scale. Accern also assigned news articles about the biotechnology company an impact score of 46.4028110554215 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

Here are some of the media stories that may have effected Accern Sentiment’s rankings:

RTTR has been the subject of a number of research reports. Zacks Investment Research raised Ritter Pharmaceuticals from a “hold” rating to a “buy” rating and set a $0.75 price target for the company in a research report on Tuesday, May 23rd. Maxim Group reaffirmed a “hold” rating on shares of Ritter Pharmaceuticals in a research report on Tuesday, May 9th. Finally, Chardan Capital lowered their price target on Ritter Pharmaceuticals from $3.50 to $1.50 and set a “buy” rating for the company in a research report on Tuesday, August 8th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Ritter Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $4.88.

Ritter Pharmaceuticals (NASDAQ RTTR) traded down 1.6491% during trading on Friday, hitting $0.5606. The company’s stock had a trading volume of 81,912 shares. The company has a 50-day moving average of $0.57 and a 200 day moving average of $1.23. Ritter Pharmaceuticals has a one year low of $0.50 and a one year high of $3.75. The firm’s market cap is $8.27 million.

Ritter Pharmaceuticals (NASDAQ:RTTR) last announced its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.14) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.14). On average, equities analysts forecast that Ritter Pharmaceuticals will post ($0.42) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “Ritter Pharmaceuticals (RTTR) Given Daily Media Impact Score of 0.01” was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this news story on another site, it was copied illegally and republished in violation of United States & international copyright and trademark law. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2017/08/27/ritter-pharmaceuticals-rttr-given-daily-media-impact-score-of-0-01.html.

About Ritter Pharmaceuticals

Ritter Pharmaceuticals, Inc develops therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company’s segment is focusing on the development and commercialization of RP-G28. The Company conducts human gut health research by exploring metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into applications intended to have impact on a patient’s health.

Insider Buying and Selling by Quarter for Ritter Pharmaceuticals (NASDAQ:RTTR)

Receive News & Stock Ratings for Ritter Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ritter Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.